EŠEva Klara Merzel Šabović

Eva Klara Merzel Šabović

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eva Klara Merzel Šabović has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    GLP-1 receptor agonists and lymphedema: from weight loss to potential direct modulation of lymphatic function

    by Eva Klara Merzel Šabović, Miodrag Janić, Tanja Planinšek Ručigaj

    Obesity and lymphedema are linked through increased interstitial fluid load, impaired collecting-vessel pumping, inflammation, and progressive fibro-adipose remodeling. This bidirectional relationship makes glucagon-like peptide-1 receptor agonists (GLP-1RAs) relevant through two potentially distinct pathways. First, substantial weight loss may unload a compromised lymphatic system, improve mobility, and reduce adipose-driven inflammation. Second, GLP-1 signaling may directly influence lymphatic vessel function. Case reports and a retrospective cohort have described reduced limb volume, improved symptoms or imaging findings, and a lower incidence of breast cancer-related lymphedema among GLP-1RA users. Experimental work has identified GLP-1 receptors in lymphatic endothelial cells and shown that pharmacological activation with semaglutide increases the pumping capacity of isolated collecting lymphatic vessels. These findings support a potential direct lymphatic effect but do not establish clinical efficacy in human lymphedema. Improvement during treatment may instead reflect reduced fat mass, greater mobility, or changes in conventional care. Future studies should distinguish weight-loss-dependent unloading from weight-loss-independent effects by combining standardized clinical outcomes, functional imaging, body-composition measurements, and, where feasible, weight-matched comparison groups. The available evidence therefore supports prospective investigation rather than clinical adoption. Trials should assess early vascular responses before major weight loss, longer-term changes in tissue composition and inflammation, and durability after treatment withdrawal, while maintaining standardized compression, exercise, skin care, and other components of established lymphedema management throughout. Until such evidence is available, GLP-1RAs should be prescribed for established metabolic indications rather than lymphedema itself, and any lymphatic benefit should be regarded as a promising clinical signal rather than a treatment claim.

  • Open Access

    Is incretin therapy the missing link to silencing residual inflammation in biologic-treated psoriasis?

    by Eva Klara Merzel Šabović, Miodrag Janić

    1. Psoriasis is a chronic immune-mediated systemic inflammatory disease that affects about 2%–3% of the global population. It is strongly linked to obesity, with excess body weight reported in 60%–...

  • Open Access

    Psychological distress in young adults with well-controlled psoriasis

    by Eva Klara Merzel Šabović, Tadeja Kraner Šumenjak, Miodrag Janić

    Introduction: Psychological distress is common in psoriasis, but its prevalence and possible biological correlates in young adults with well-controlled disease remain unclear. In this study, we aimed to assess the presence of anxiety and depressive symptoms in young, well-treated psoriasis patients, who were primarily expected to have no or minimal psychological distress, and to explore potential associations with inflammatory and metabolic markers. Methods: In a cross-sectional cohort of 80 psoriasis patients (women/male: 45/35; mean age 38.7 ± 4.2 years) psychological symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS), with HADS-A and HADS-D subscales evaluating anxiety and depression symptoms. Exploratory associations with inflammatory cytokines and metabolic indices were examined using regression analyses and random forest machine-learning models. Results: Anxiety symptoms were identified only in 5 patients (women/male: 4/1; 6%), and depressive symptoms in 10 patients (women/male: 6/4; 12%). Affected individuals had clinically significant anxiety (HADS-A: 12/21) and borderline depressive symptoms (HADS-D: 10/21). No significant associations between HADS scores and inflammatory or metabolic markers were found. Exploratory random forest models tentatively identified IL-6, IL-23, FIB-4, HOMA-IR, and waist circumference as the strongest contributors to variance in depressive symptoms, while no clear contributors emerged for anxiety. Discussion: Anxiety and depressive symptoms can occur in well-treated young psoriasis patients. Although prevalence is low, their impact may be substantial. These findings indicate the potential importance of targeted psychological screening in this population. Associations with inflammatory and metabolic markers should be considered hypothesis-generating and warrant validation in larger, independent cohorts.

  • Open Access

    Overall hemostatic potential as a marker of subclinical hypercoagulability in treated psoriasis patients

    by Eva Klara Merzel Šabović, Tadeja Kraner Šumenjak, Mojca Božič Mijovski, Miodrag Janić

    Background: Psoriasis is associated with increased cardiovascular risk, possibly mediated by inflammation-induced hemostatic dysregulation and hypercoagulability. However, these changes are often difficult to detect with conventional markers.Objectives: To assess hypercoagulability in patients with psoriasis using the Overall Hemostatic Potential (OHP) test, a global integrative test for coagulation and fibrinolysis.Methods: We studied 80 psoriasis patients (54 men, 26 women, aged 30–45 years) receiving effective topical or systemic treatments (methotrexate, adalimumab, secukinumab or guselkumab) and compared them with 20 healthy controls. We measured OHP, its components — overall coagulation potential (OCP) and overall fibrinolytic potential (OFP) and selected hemostatic markers (platelet count, mean platelet volume, platelet-to-lymphocyte ratio, P-selectin, D-dimer and fibrinogen).Results: Psoriasis patients had significantly higher OHP levels, primarily due to decreased OFP, while OCP levels were comparable to the control group — indicating a hypercoagulable state due to impaired fibrinolysis. Other conventional hemostatic markers showed no significant differences. OHP and OFP correlated with residual inflammatory activity, BMI, waist circumference, visceral adiposity and fibrinogen levels, suggesting a relationship between subclinical inflammation, metabolic parameters and hemostatic imbalance.Conclusion: The OHP test reveals a hypercoagulable state in psoriasis patients even in the absence of abnormal standard coagulation markers. OHP could be a practical and sensitive tool to stratify cardiovascular risk in psoriasis, especially in patients with concomitant metabolic disease or persistent inflammation.


  • Open Access

    Residual non-specific and disease-specific inflammatory markers in successfully treated young psoriasis patients: a cross-sectional study

    by Eva Klara Merzel Šabović, Tadeja Kraner Šumenjak, Mojca Božič Mijovski, Miodrag Janić

    Psoriasis is a chronic, immune-mediated disease. The systemic inflammation triggered by psoriasis contributes significantly to increased cardiovascular risk. While various treatments completely clear the skin, the associated effects on systemic inflammation are not yet clear. We investigated residual systemic inflammation in successfully treated patients. Circulating disease-specific and non-specific inflammatory markers were measured and compared in 80 psoriasis patients (aged 30–45 years) successfully treated with topical therapy, methotrexate, adalimumab, secukinumab or guselkumab, and in 20 healthy controls. Non-specific inflammatory markers (high-sensitivity C-reactive protein (hs-CRP), complete blood count (CBC) parameters, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), mean platelet volume-to-platelet ratio (MPR), and red blood cell distribution width-to-platelet ratio (RPR)) and disease-specific inflammatory markers (interferon-γ (IFN-γ), tumor necrosis factor (TNF), interleukin (IL)-1β, IL-12p70, IL-17, and IL-23) were measured and compared between groups. Disease-specific cytokines (IFN-γ, TNF, IL-1β, IL-12p70, and IL-17, but not IL-23), were significantly elevated in patients compared to controls, while non-specific inflammatory markers showed no differences compared to controls. The residual disease-specific cytokines were similarly elevated in all five treated groups. In addition, they correlated significantly with body mass index (BMI) and waist circumference. Our results suggest that psoriasis patients have elevated residual disease-specific cytokines despite successful treatment, while the non-specific inflammatory markers are similar to those in control subjects. Residual disease-specific inflammatory markers correlated with BMI and waist circumference. A possible beneficial effect of body weight control in psoriasis patients merits further investigation. The study was registered at http://clinicaltrials.gov (identifier: NCT05957120) on July 24, 2023.


  • Prevalence of Pre-Existing Subclinical Leg Lymphedema in Patients with Erysipelas

    by Eva Klara Merzel Šabović, Tanja Planinšek Ručigaj

    Background: Erysipelas is a common bacterial infection of the skin and subcutaneous tissue. In certain patients, the triggering factor can be identified, but in many cases, it remains elusive. Prior research indicates that pre-existing subclinical lymphedema in patients might serve as a triggering factor for the development of erysipelas. Objectives: We investigated the prevalence of subclinical lymphedema on the unaffected leg in patients with a recent history of erysipelas by performing lymphoscintigraphy of both legs. Methods: In a prospective study, 106 consecutive patients (mean age 53.4 years; 87/19: men/women) 3 to 6 months after erysipelas episode were included in the study. In all patients, lymphoscintigraphy was performed by subcutaneous injection of Tc-99m-labelled human albumin into both feet according to standard protocol. Results: Subclinical lymphedema on the unaffected leg was found in 82% of patients, with a similar prevalence in all genders and age groups, and in patients with or without erysipelas risk factors. Moreover, the prevalence of subclinical lymphedema increased proportionally with the number of erysipelas episodes: among those with a single episode, 74% exhibited subclinical lymphedema, whereas among those with 3 or more episodes, the prevalence was 100%. Conclusions: We found a high prevalence of subclinical lymphedema in the unaffected leg in erysipelas patients, indicating its frequent bilateral occurrence and its role as a primary trigger of erysipelas. Moreover, our study highlights subclinical lymphedema as a risk factor for erysipelas recurrences. Thus, our clinical recommendation suggests bilateral leg compression therapy in erysipelas patients to prevent recurrence and lymphedema exacerbation.


  • Open Access

    Arterial function is preserved in successfully treated patients with psoriasis vulgaris

    by Eva Klara Merzel Šabović, Tadeja Kraner Šumenjak, Mojca Božič Mijovski, Miodrag Janić

    Introduction: Endothelial dysfunction is an early precursor of atherosclerosis and is common in patients with psoriasis, presumably primarily due to psoriasis-related inflammation. We investigated endothelial function, arterial stiffness, and circulating markers of endothelial activation in young patients with psoriasis vulgaris of varying severity, all of whom were effectively treated achieving PASI 90. Methods: We conducted a cross-sectional study of 80 patients (54 men/26 women, 30–45 years) who were effectively treated with topical therapy, methotrexate, adalimumab, secukinumab or guselkumab, and 20 healthy controls. Endothelial dysfunction was measured by flow-mediated dilation and arterial stiffness was measured by pulse wave velocity and common carotid artery stiffness. The following circulating biomarkers of endothelial activation were measured: ICAM-1, VCAM-1, E- and P-selectin, GDF-15, and TRAIL. Results: Endothelial function and arterial stiffness parameters did not differ between patients with effectively treated psoriasis and the control group. Circulating endothelial activation biomarkers did not show relevant differences between the groups of effectively treated patients or controls. Discussion: Although cardiovascular disease is the leading cause of morbidity and mortality in patients with psoriasis, effective antipsoriatic treatment appears to slow the progression of atherosclerosis, even when there are cardiovascular risk factors, such as smoking or obesity. This may suggest that antipsoriatic treatment exerts a cardioprotective effect. Conclusions: Our results suggest that early and effective treatment of varying-severity psoriasis vulgaris in young patients appears to prevent arterial dysfunction related to psoriasis and consequent cardiovascular risk. The study is registered at http://clinicaltrials.gov (identifier: NCT05957120).


  • Open Access

    Residual metabolic burden in young psoriasis patients successfully treated with biologics

    by Eva Klara Merzel Šabović, Tadeja Kraner Šumenjak, Miodrag Janić

    Metabolic disorders are common in patients with psoriasis and contribute significantly to an increased cardiovascular risk. While biologic therapy is very successful in clearing skin lesions, its impact on metabolic parameters is uncertain. Our aim was to investigate the residual metabolic burden in psoriasis patients successfully treated with biologic therapy. We conducted a cross-sectional study of 80 young patients (54 men, 26 women, aged 30–45 years) successfully treated with either adalimumab, secukinumab or guselkumab and topical therapy or methotrexate, and 20 healthy controls. Anthropometric parameters, lipid levels and metabolic indices (HOMA-IR, TyG index and FIB-4 index) were measured. Patients did not receive any other treatments to exclude confounding effects. After analysis, we found that patients treated with three different biologics had similar metabolic status, only the FIB-4 index was higher in the adalimumab group than in the secukinumab and guselkumab treatment groups. There were no significant differences between the patients treated with biologics and the control group. The comparison with patients treated topically or with methotrexate showed that only triglyceride levels, HOMA-IR, TyG index, and FIB-4 index were elevated in patients treated with adalimumab compared to patients treated with topical therapy. Finally, metabolic status was also similar in patients treated with methotrexate or topical therapy. In conclusion, this study suggests that psoriasis patients successfully treated with biologics have similar metabolic parameters to the control group and patients treated with topical therapy or methotrexate. This indicates that there is no significant residual metabolic burden in young patients successfully treated with biologics. These results are clinically relevant and should be considered in the treatment of psoriasis patients.The study is registered at http://clinicaltrials.gov (identifier: NCT05957120). Date of registration: 24th of July 2023.


  • Open Access

    Microblading reaction as a manifestation of systemic sarcoidosis: two case reports and a review of the literature

    by Eva Klara Merzel Šabović, Mateja Starbek Zorko, Violeta Hosta, Borut Žgavec, Vid Bajuk

    Background: Sarcoidosis is a multisystemic disease characterized by granulomatous inflammation. Sarcoidosis often poses a diagnostic challenge owing to its nonspecific or mild clinical features. In 20–35% of cases, sarcoidosis initially presents on skin. However, skin lesions commonly mimic dermatological conditions. Therefore, it is important to not underestimate the skin manifestations and perform histopathological examinations to make a timely diagnosis. Case presentation: We present two cases of 33-year-old Caucasian female patients with orange–red macules and plaques that developed in the eyebrow area 1 and 6 years after microblading, respectively. Histopathological examination confirmed a diagnosis of sarcoidosis. The lymph nodes and lungs were also affected in both patients. Conclusion: Our two reports suggest that an esthetic procedure involving dermal or subcutaneous injection of foreign materials can trigger the development of cutaneous and systemic sarcoidosis. However, this relationship has not been described yet. Physicians should, therefore, be aware of this complication to properly evaluate and treat such patients in a timely manner.